These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 10914117)
1. What should I do for low HDL? Lavie CJ Postgrad Med; 2000 Jul; 108(1):25-6. PubMed ID: 10914117 [No Abstract] [Full Text] [Related]
2. The emerging role of HDL cholesterol. Is it time to focus more energy on raising high-density lipoprotein levels? Safeer RS; Cornell MO Postgrad Med; 2000 Dec; 108(7):87-90, 93-8. PubMed ID: 11126145 [TBL] [Abstract][Full Text] [Related]
3. [Significance of HDL cholesterol increase for the risk reduction. Methods of intervention. recommendations of experts]. Kardiol Pol; 2005 Jun; 62 Suppl 2():II5-12. PubMed ID: 19813328 [No Abstract] [Full Text] [Related]
4. Nicotinic acid and HDL-C reduction. S Afr Med J; 2005 Feb; 95(2):89. PubMed ID: 15751197 [No Abstract] [Full Text] [Related]
5. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014 [TBL] [Abstract][Full Text] [Related]
6. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C; Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528 [TBL] [Abstract][Full Text] [Related]
7. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy. Duvall WL; Blazing MA; Saxena S; Guyton JR J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203 [TBL] [Abstract][Full Text] [Related]
8. Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease. Lavie CJ; Mailander L; Milani RV Am J Cardiol; 1992 Apr; 69(12):1083-5. PubMed ID: 1561983 [No Abstract] [Full Text] [Related]
9. High-density lipoprotein cholesterol and coronary heart disease. Young CE; Karas RH; Kuvin JT Cardiol Rev; 2004; 12(2):107-19. PubMed ID: 14766026 [TBL] [Abstract][Full Text] [Related]
10. Niacin as a component of combination therapy for dyslipidemia. Miller M Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785 [TBL] [Abstract][Full Text] [Related]
11. [Relations between HDL-cholesterol and cardiovascular diseases]. Emmerich J; Bruckert E; Delahaye F; Thomas D; Richard JL Arch Mal Coeur Vaiss; 1992 Oct; 85 Spec No 3():21-8. PubMed ID: 1296542 [TBL] [Abstract][Full Text] [Related]
12. The role of treatment to increase HDL-cholesterol and decrease triglyceride concentrations in prevention of coronary heart disease in Type 2 diabetes. Wild S; Byrne CD Diabet Med; 2004 Sep; 21 Suppl 4():8-11. PubMed ID: 15315518 [No Abstract] [Full Text] [Related]
13. Antioxidant versus lipid-altering therapy--some answers, more questions. Freedman JE N Engl J Med; 2001 Nov; 345(22):1636-7. PubMed ID: 11757512 [No Abstract] [Full Text] [Related]
19. Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN. J Am Board Fam Pract; 1991; 4(5):285-97. PubMed ID: 1746296 [TBL] [Abstract][Full Text] [Related]
20. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]